DOCSLIB.ORG

Lunivia, INN-Eszopiclone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lunivia, INN-Eszopiclone European Medicines Agency WITHDRAWAL ASSESSMENT REPORT FOR Lunivia International Non-proprietary Name: eszopiclone Procedure No. EMEA/H/C/000895 Final Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE ........................................... 3 1.1. Submission of the dossier ........................................................................................................ 3 1.2. Steps taken for the assessment of the product.......................................................................... 3 1.3. Steps taken for the re-examination procedure.......................................................................... 4 2. SCIENTIFIC DISCUSSION................................................................................................. 5 2.1. Introduction.............................................................................................................................. 5 2.2. Quality aspects ......................................................................................................................... 5 2.3. Non-clinical aspects ................................................................................................................. 9 2.4. Clinical aspects ...................................................................................................................... 16 2.5. Pharmacovigilance................................................................................................................. 53 2.6. Overall conclusions, risk/benefit assessment and recommendation ...................................... 59 3.7 New Active Substance status (NAS)...................................................................................... 61 3. RE-EXAMINATION OF THE CHMP OPINION ........................................................... 65 3.1. Grounds for re-examination ................................................................................................... 65 3.2. Detailed Positions .................................................................................................................. 68 3.3. CHMP Overall conclusions from the Joined Assessment Report.......................................... 98 3.4. The following questions were addressed by the CHMP to the Clinical Neurosciences Scientific Advisory Group...................................................................................................................... 98 th 3.5. Questions addressed during the Oral Explanation on 16 February 2009............................. 99 3.6. Overall conclusions of the re-examination procedure.......................................................... 101 Lunivia 2/101 1. BACKGROUND INFORMATION ON THE PROCEDURE 1.1. Submission of the dossier The applicant Sepracor Pharmaceuticals, Ltd. submitted on 23 July 2007 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Lunivia, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 27 February 2007. The legal basis for this application refers to: A - Centralised / Article 8(3) / New active substance. Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application The application submitted is a complete dossier: Composed of administrative information, complete quality data, non-clinical and clinical data based on applicants’ own tests and studies The applicant applied for the following indication treatment of insomnia. Licensing status: Lunivia has been given a Marketing Authorisation in US on 15 December 2004 (marketed as product called Lunesta). The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Dr David Lyons Co-Rapporteur: Prof Cristina Sampaio 1.2. Steps taken for the assessment of the product • The application was received by the EMEA on 23 July 2007. • The procedure started on 15 August 2007. • The Rapporteur's first Assessment Report was circulated to all CHMP members on 7 November 2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 14 November 2007. In accordance with Article 6(3) of Regulation (RC) No 726/2004, the Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days. • During the meeting on 10-13 December 2007, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 14 December 2007. • The applicant submitted the responses to the CHMP consolidated List of Questions on 28 March 2008. • The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of Questions to all CHMP members on 12 May 2008. • During the CHMP meeting on 27-29 May 2008, the CHMP agreed on a list of outstanding issues to be addressed in writing and in an oral explanation by the applicant. • During the CHMP meeting on 22-25 September 2008, outstanding issues were addressed by the applicant during an oral explanation before the CHMP. • During the meeting on 20-23 October 2008, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Lunivia on 23 October 2008. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 17 October 2008. Lunivia 3/101 1.3. Steps taken for the re-examination procedure • The applicant submitted written notice to the EMEA on 04 November 2008 to request a re-examination of the Lunivia CHMP positive opinion of 23 October 2008. • During its meeting on 15-18 December 2008, the CHMP appointed Dr. K. Broich as Rapporteur and Dr Votava as Co-Rapporteur. The Rapporteur and Co-Rapporteur appointed by the CHMP and the re-examination evaluation teams were: Rapporteur: Dr Karl Broich Co-Rapporteur: Dr Martin Votava • The detailed grounds for the re-examination request were submitted by the applicant on 23 December 2008. The re-examination procedure started on 23 December 2008. • The Rapporteur's Assessment Report was circulated to all CHMP members on 28 January 2009. The Co-Rapporteur's Assessment Report was circulated to all CHMP members on 23 January 2009. • During its meeting on 19-22 January 2009, the CHMP adopted a List of Participants for the Scientific Advisory Group (SAG) meeting on Clinical Neuroscience meeting to be held on 5 February 2009. • During the SAG meeting on 5 February 2009, experts were convened to consider the grounds for re-examination. During this meeting the applicant presented an oral explanation. A report of this meeting was forwarded to the CHMP. • The Rapporteurs’ Joint Assessment Report was circulated to all CHMP members on 11 February 2009. • During the CHMP meeting on 16 - 19 February 2009, the applicant presented an oral explanation before the CHMP on 16 February 2009. • During the meeting on 16 – 19 February 2009, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a final Opinion confirming the favourable benefit/risk balance of Lunivia as determined in the original opinion of October 2008. However, the CHMP also reconfirmed its opinion of October 2008, concluding that no meaningful clinical difference could be established between eszopiclone and zopiclone regarding safety and efficacy and therefore recommending the refusal of the New Active Substance Status to eszopiclone. The applicant provided the revised letter of undertaking on the follow-up measures to be fulfilled on 19 February 2009. Lunivia 4/101 2. SCIENTIFIC DISCUSSION 2.1. Introduction Sepracor Pharmaceuticals Ltd. has submitted an application for a marketing authorisation through the centralised procedure for Lunivia 2 mg and 3 mg film coated tablets. Racemic zopiclone is already marketed in Europe, and eszopiclone is approved on the market in the United States of America. The product contains the active substance eszopiclone. Racemic zopiclone is a mixture of the enantiomers (S)-zopiclone and (R)-zopiclone whereas eszopiclone is comprised of pure (S)-zopiclone, a single isomer associated with hypnotic activity. The applied indication for Lunivia is for the treatment of insomnia, including difficulty falling asleep, nocturnal awakening or early awakening, in adults, usually for short term duration. Insomnia is a heterogeneous condition featuring reduced quality, duration, or efficiency of sleep; it is a common condition characterised by sleep disruption lasting at least one month. Disruption of sleep may include difficulty initiating sleep, difficulty maintaining sleep, or early morning awakening. An additional complaint is diminished sleep quality or non-restorative sleep and may cause consequent daytime impairment or distress with fatigue and poor concentration. 2.2. Quality aspects Introduction Sepracor Pharmaceuticals Ltd. has submitted an application for a marketing authorisation through the centralised procedure for Lunivia 2 mg and 3 mg film coated tablets. The product contains the active substance
Load more

Recommended publications
  • 2015-16 59. On-Line Learning Bipolar Medications
    Pharmacology/Therapeutics II Block II Handouts – 2015‐16 59. On‐Line learning Bipolar Medications ‐ Schilling 60. On‐Line Learning Anti‐Depressants ‐ Schilling 61. On‐Line Learning Sedative Hypnotics ‐ Battaglia 62. On‐Line Learning Treatment of Insomnia ‐ Battaglia 63. On‐Line Learning AntiPsychotics ‐ Schilling 64. On‐Line Only Drugs of Abuse, tolerance & Dependence – Bakowska 65. Active Learning Session: Mood Disorders & Treatment – Schilling 66. Active Learning Session – Anxiety Disorders – Schilling 67. Active Learning Session – Psychotic Illness & Treatment – Schilling 68. Drugs to Treat Rheumatoid Arthritis & Gout ‐ Clipstone Pharmacology & Therapeutics Bipolar Medications February 15, 2016 David Schilling, M.D. Bipolar Disorder Medications Goals & Objectives: Describe the pharmacologic profiles of major drugs/drug classes used in the treatment of bipolar disorder. These drugs include: Lithium, Divalproex (Depakote), Carbamazepine (Tegretol), Lamotrigine (Lamictal) 1. List the major drugs/drug classes used in the treatment of bipolar disorder 2. Describe the mechanism of action of each of the major drugs/drug classes used in the treatment of bipolar disorder 3. Describe the principle pharmacokinetic properties of the major drugs used to treat bipolar disorder. This includes: half-life & time to steady state, trough levels, metabolic auto-induction, P450 system induction, therapeutic index 4. Describe the pharmacodynamics (common adverse effects) of the major drugs used to treat bipolar disorder. 5. Describe the pharmacodynamics (serious adverse effects) of the major drugs used to treat bipolar disorder. This includes: lithium toxicity, agranulocytosis, aplastic anemia, hepatic failure, exfoliative dermatitis, pancreatitis, Steven’s Johnson syndrome 6. Identify the laboratory tests that may be used to monitor for common and serious major adverse effects of the major drugs used to treat bipolar disorder.
    [Show full text]
  • Lunesta: Uses, Dosage, Side Effects ­ Drugs.Com
    4/5/2017 Lunesta: Uses, Dosage, Side Effects ­ Drugs.com Lunesta ﴿Generic Name: eszopiclone ﴾e ZOP i klone Brand Names: Lunesta What is Lunesta? Lunesta ﴾eszopiclone﴿ is a sedative, also called a hypnotic. It affects chemicals in your brain that may be unbalanced in people .﴿with sleep problems ﴾insomnia Lunesta is used to treat insomnia. This medicine causes relaxation to help you fall asleep and stay asleep. Lunesta may also be used for purposes not listed in this medication guide. Important information Lunesta may cause a severe allergic reaction. Stop taking this medicine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Lunesta will make you fall asleep. Never take this medication during your normal waking hours, unless you have at least 8 hours to dedicate to sleeping. Some people using this medicine have engaged in activity such as driving, eating, or making phone calls and later having no memory of the activity. If this happens to you, stop taking Lunesta and talk with your doctor about another treatment for your sleep disorder. Lunesta can cause sie effects that may impair your thinking or reactions. You may still feel sleepy the morning after taking the medication. Until you know how this medication will affect you during waking hours, be careful if you drive, operate machinery, pilot an airplane, or do anything that requires you to be awake and alert. Do not drink alcohol while you are taking this medication. It can increase some of the side effects, including drowsiness.
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • MEDICATION GUIDE ESZOPICLONE TABLETS CIV (Es″ Zoe Pik′ Lone
    MEDICATION GUIDE ESZOPICLONE TABLETS CIV (es″ zoe pik′ lone) 1 mg, 2 mg and 3 mg Read the Medication Guide that comes with eszopiclone tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. What is the most important information I should know about eszopiclone tablets? • Do not take more eszopiclone tablets than prescribed. • Do not take eszopiclone tablets unless you are able to stay in bed a full night (7 to 8 hours) before you must be active again. • Take eszopiclone tablets right before you get in bed, not sooner. Eszopiclone tablets may cause serious side effects that you may not know are happening to you. These side effects include: • sleepiness during the day • not thinking clearly • act strangely, confused, or upset • "sleep-walking" or doing other activities when you are asleep like: o eating o talking o having sex o driving a car Call your healthcare provider right away if you find out that you have done any of the above activities after taking eszopiclone tablets. The morning after you take eszopiclone tablets your ability to drive safely and think clearly may be decreased. Do not take eszopiclone tablets if you: • drank alcohol that evening or before bed • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take eszopiclone tablets with your other medicines • cannot get a full night’s sleep What are eszopiclone tablets? Eszopiclone tablets are a sedative-hypnotic (sleep) medicine.
    [Show full text]
  • The Safety Risk Associated with Z-Medications to Treat Insomnia in Substance Use Disorder Patients
    Riaz U, et al., J Addict Addictv Disord 2020, 7: 054 DOI: 10.24966/AAD-7276/100054 HSOA Journal of Addiction & Addictive Disorders Review Article Introduction The Safety Risk Associated Benzodiazepine receptor agonist is divided in two categories: with Z-Medications to Treat a) Benzodiazepine hypnotics and Insomnia in Substance Use b) Non-benzodiazepine hypnotics. The prescription of Z-medications which is non-benzodiazepine Disorder Patients hypnotic is common in daily clinical practice, particularly among primary medical providers to treat patients with insomnia. This trend Usman Riaz, MD1* and Syed Ali Riaz, MD2 is less observed among psychiatrist, but does exist. While treating substance use disorder population the prescription of Z-medications 1 Division of Substance Abuse, Department of Psychiatry, Montefiore Medical should be strongly discouraged secondary to well documented Center/Albert Einstein College of Medicine, Bronx NY, USA safety risks. There is sufficient data available suggesting against the 2Department of Pulmonology/Critical Care and Sleep Medicine, Virtua Health, prescription of Z-medications to treat insomnia in substance abuse New Jersey, USA patients. Though treating insomnia is essential in substance use disorder patients to prevent relapse on alcohol/drugs, be mindful of risk associated with hypnotics particularly with BZRA (Benzodiazepines Abstract and Non benzodiazepines hypnotics). Z-medications are commonly prescribed in clinical practices Classification of Z-medications despite the safety concerns. Although these medications are Name of medication Half-life (hr) Adult dose (mg). considered safer than benzodiazepines, both act on GABA-A receptors as an allosteric modulator. In clinical practice, the risk Zaleplon 1 5-20 profile for both medications is not any different, particularly in Zolpidem 1.5-4.5 5-10 substance use disorder population.
    [Show full text]
  • The Effects of Eszopiclone on Sleep Spindles and Memory Consolidation in Schizophrenia: a Randomized Placebo-Controlled Trial Erin J
    EFFECTS OF ESZOPICLONE ON SLEEP AND MEMORY IN SCHIZOPHRENIA http://dx.doi.org/10.5665/sleep.2968 The Effects of Eszopiclone on Sleep Spindles and Memory Consolidation in Schizophrenia: A Randomized Placebo-Controlled Trial Erin J. Wamsley, PhD1; Ann K. Shinn, MD, MPH2; Matthew A. Tucker, PhD1; Kim E. Ono, BS3; Sophia K. McKinley, BS1; Alice V. Ely, MS1; Donald C. Goff, MD3; Robert Stickgold, PhD1; Dara S. Manoach, PhD3,4 1Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MA; 2Psychotic Disorders Division, McLean Hospital, Belmont, MA; 3Department of Psychiatry, Massachusetts General Hospital, Charlestown, MA; 4Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA Study Objectives: In schizophrenia there is a dramatic reduction of sleep spindles that predicts deficient sleep-dependent memory consolidation. Eszopiclone (Lunesta), a non-benzodiazepine hypnotic, acts on γ-aminobutyric acid (GABA) neurons in the thalamic reticular nucleus where spindles are generated. We investigated whether eszopiclone could increase spindles and thereby improve memory consolidation in schizophrenia. Design: In a double-blind design, patients were randomly assigned to receive either placebo or 3 mg of eszopiclone. Patients completed Baseline and Treatment visits, each consisting of two consecutive nights of polysomnography. On the second night of each visit, patients were trained on the motor sequence task (MST) at bedtime and tested the following morning. Setting: Academic research center. Participants: Twenty-one chronic, medicated schizophrenia outpatients. Measurements and Results: We compared the effects of two nights of eszopiclone vs. placebo on stage 2 sleep spindles and overnight changes in MST performance. Eszopiclone increased the number and density of spindles over baseline levels significantly more than placebo, but did not significantly enhance overnight MST improvement.
    [Show full text]
  • Last Review Status/Date
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.11 Section: Prescription Drugs Effective Date: January 1, 2020 Subsection: Central Nervous System Drugs Original Policy Date: December 7, 2011 Subject: Sedative Hypnotics Page: 1 of 7 Last Review Date: December 6, 2019 Sedative Hypnotics Description Ambien (zolpidem), Ambien CR (zolpidem extended-release), Dalmane (flurazepam), Edluar (zolpidem sublingual), Halcion (triazolam), Intermezzo (zolpidem sublingual) Lunesta (eszopiclone), Prosom (estazolam), Restoril (temazepam), Sonata (zaleplon), Zolpimist (zolpidem) Oral Spray Background Insomnia is defined as complaints of disturbed sleep in the presence of adequate opportunity and circumstance for sleep. The disturbance can consist of one or more of three features: difficulty in initiating sleep; difficulty in maintaining sleep; or waking up too early. Insomnia can be primary or secondary to a variety of medical illnesses, psychiatric disorders, or drug use. Identifying and treating potential underlying conditions or comorbid diagnoses are priorities in the treatment of insomnia. In order to treat insomnia, various treatment modalities should be considered, such as sleep hygiene, sleep restriction, stimulus control and cognitive behavioral therapy, prior to the addition of pharmacotherapy, and continued throughout pharmacotherapy treatment (1-2). The treatment of insomnia should be individualized and is dependent on the differential diagnosis. Although short-term therapy is appropriate for most patients, some patients may benefit from long-term use. Patients with insomnia that occurs several days per week and lasts for more than a month may have the diagnosis of chronic insomnia. There are indications that long-term management of chronic insomnia may be beneficial.
    [Show full text]
  • Insomnia Medications – Safety Communication and Updated Labeling
    Insomnia medications – Safety communication and updated labeling • On April 30, 2019, the FDA announced that a Boxed Warning will be added to the drug labels of certain common prescription insomnia medications due to rare but serious injuries occurring because of complex sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake. — These complex sleep behaviors have also resulted in deaths. — These behaviors appear to be more common with eszopiclone (Lunesta®), zaleplon (Sonata®), and zolpidem (eg, Ambien®, Ambien CR®, Edluar®, Intermezzo®, and Zolpimist™) than other prescription medications used for sleep. — The FDA is also requiring an update to the Contraindication section of the drug labels, to avoid use of these medications in patients who have previously experienced an episode of complex sleep behavior with eszopiclone, zaleplon, and zolpidem. — This information will also be added to the patient Medication Guides. • Drugs such as eszopiclone, zaleplon, and zolpidem are prescription sedative-hypnotic medications used to treat insomnia in adults who have difficulty falling asleep or staying asleep. • Patients should stop taking their insomnia medication and contact their health care professional right away if they experience a complex sleep behavior where they engage in activities while they are not fully awake or if they do not remember activities they have done while taking the medication. • Healthcare professionals should not prescribe eszopiclone, zaleplon, or zolpidem to patients who have previously experienced complex sleep behaviors after taking any of these medications. All patients should be advised that although rare, the behaviors caused by these medications have led to serious injuries or death.
    [Show full text]
  • Eszopiclone-Lunesta-Monograph.Pdf
    Eszopiclone (Lunesta) Classification: Hypnotic Pharmacology The mechanism of action of eszopiclone (Lunesta) as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors. Indication -FDA & literature supported non-FDA Treatment of insomnia (decreased sleep latency and improved sleep maintenance) Pharmacokinetics Pharmacokinetic Parameter Details Absorption Rapidly absorbed. Peak plasma concentrations achieved within approximately 1 hour after oral administration Distribution Weakly bound to plasma protein (52-59%) Metabolism Hepatic via oxidation and demethylation (CYP2E1, 3A4); (S)- N-desmethyl zopiclone metabolite has less activity than parent compound Excretion Urine (up to 75%, primarily as metabolites; < 10% as parent drug) 1 Texas Health and Human Services ● hhs.texas.gov T-max Oral Elimination Dose Z-drug (h) bioavailability t ½ (h) range Metabolism Zolpidem 1-2 65-70% 2.5-3 5-10 mg CYP 3A4, IR 2C9, 1A2 Zolpidem 1.5-2.5 65-70% 2.5-3 6.25-12.5 ER mg Zopiclone 1.5-2 75-80% 5-6 3.75-7.5 CYP 3A4, 2C8 Eszopiclone 1-1.5 75-80% 6-7 1-3 mg CYP 3A4, 2E1 Zaleplon 0.7-1.4 30% 1 5-20 mg Aldehyde oxidase, CYP 3A4 Dosage/Administration The recommended starting dose in adults is 1 mg, once daily immediately before bedtime. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose should not exceed 2 mg in elderly or debilitated patients. No dose adjustment is necessary for patients with mild-to-moderate hepatic impairment.
    [Show full text]
  • Medications for Insomnia: Drug Information to Support Drug Therapy Decisions B.C
    Medications for Insomnia: Drug Information to Support Drug Therapy Decisions B.C. Provincial Academic Detailing (PAD) Service December 2020 Learning Objectives: Participants in this PAD session will have the opportunity to discuss: . The strength of recommendations for and against specific medications for insomnia in contemporary clinical practice guidelines . Prescribing principles applicable to medications for insomnia . Drug information relevant to the prescribing, deprescribing and monitoring of medications for insomnia with a focus on the most commonly prescribed medications BC’s Provincial Academic Detailing (PAD) Service is offered free of charge to health care professionals. The service is provided by health authorities and supported by the Ministry of Health. Relevant topics are identified in consultation with various groups. All written materials are externally reviewed by clinicians and experts in critical appraisal. Medications for Insomnia: Evidence to Practice Apply prescribing principles Clinical practice guidelines that include: Many people in British Columbia make weak recommendations are prescribed higher than the for and against specific . discussion of goals of therapy recommended doses of BZRAs, medications, reflecting . medication review such as zopiclone. To reduce uncertainty in the evidence for . attention to dose & drug the risk of next day impairment, medication benefits interactions Health Canada has lowered versus harms. communication of risk starting and maximum doses. review of ongoing use BZRAs: benzodiazepine receptor agonists (zopiclone, eszopiclone, zolpidem) Medications for Insomnia: Prescribing Principles Use low starting doses Decisions about Ask patients Review for medications and note changes to the effectiveness can be “What do you hope that can cause Implement maximum doses of made early. The drug to achieve with insomnia & consider non-pharmacologic benzodiazepine receptor approval process insomnia the potential for strategies.1-3 agonists (intended to requires evidence of treatment?”1 prescribing cascades.
    [Show full text]
  • High-Risk Medications in the Elderly
    High-Risk Medications in the Elderly The Centers for Medicare & Medicaid Services (CMS) contracted with the National Committee for Quality Assurance (NCQA) to develop clinical strategies to monitor and evaluate the quality of care provided to Medicare beneficiaries. The NCQA’s Geriatric Measurement Advisory Panel identified several categories of medications that have an increased risk of adverse effects to elderly patients. The enclosed chart identifies several key medication categories that CMS and NCQA are monitoring. In an effort to ensure patients’ safety, many of our clients have established pre-authorization protocols for those prescriptions for high risk medications in patients older than 65 years of age. Since pharmacists have a very important role in patient care, we want you to be part of this safety initiative. We strongly encourage that you contact the prescriber when your elderly patient is requesting a new or refilled prescription of a high-risk medication listed on the below chart. Category High Risk Medications Alternatives Analgesics butalbital/APAP Mild Pain: butalbital/APAP/caffeine (ESGIC, FIORICET) acetaminophen, codeine, short-term NSAIDs butalbital /APAP/caffeine/codeine Moderate/Severe Pain: butalbital/ASA/caffeine (FIORINAL) tramadol (ULTRAM), tramadol/APAP* (ULTRACET), butalbital/ASA/caffeine/codeine morphine sulfate (MS CONTIN), ketorolac (TORADOL) hydrocodone/APAP (VICODIN, etc.), oxycodone indomethacin (INDOCIN) (OXYIR), oxycodone/APAP (PERCOCET), fentanyl meperidina (DEMEROL) patch (DURAGESIC), OXYCONTIN
    [Show full text]
  • Insomnia in Patients with Addictions: a Safer Way to Break the Cycle
    Insomnia in patients with addictions: A safer way to break the cycle Fight relapse by improving sleep with nonaddictive agents and behavior therapy ® Dowden Health Media rom alcohol to opioids, most addictive substances can induce sleep disturbances that persist despite Fabstinence and mayCopyright increase theFor risk forpersonal relapse. use only Nearly all FDA-approved hypnotics are Schedule IV controlled substances that—although safe and effective for most populations—are prone to abuse by patients with substance use disorders. You’re not alone if you hesitate to prescribe hypnot- BISSELL ics to these patients; a study of 311 addiction medicine physicians found that they prescribed sleep-promoting medication to only 30% of their alcohol-dependent pa- tients with insomnia.1 IMAGES/CHRISTOPHER This article presents evidence on how alcohol and GETTY other substances disturb sleep in patients with addic- 2008 © tions. We discuss the usefulness of hypnotics, off-label sedatives, and cognitive-behavioral therapy (CBT). Our Deirdre Conroy, PhD Clinical assistant professor of psychiatry goal is to help you reduce your patients’ risk of relapse by addressing their sleep complaints. J. Todd Arnedt, PhD Clinical assistant professor of psychiatry and neurology Kirk J. Brower, MD Workup: 3 principles Associate professor of psychiatry Insomnia is multifactorial. Don’t assume that sub- stance abuse is the only cause of prominent insomnia University of Michigan Ann Arbor complaints. Insomnia in patients with substance use dis- orders may be a manifestation of protracted withdrawal or a primary sleep disorder. Evaluate your patient’s: • other illnesses (psychiatric, medical, and other sleep disorders) • sleep-impairing medications (such as activating Current Psychiatry antidepressants and theophylline) Vol.
    [Show full text]